None of the 158 patients had CD at the onset of APS-1 while 4/158 (2.5%) tissue transglutaminase autoantibodies-IgA (tTgAbs-IgA)-positive patients developed CD by the end of follow-up (Fig. 1). The gene discussed is TGM2; the disease is Autoimmune polyendocrinopathy type 1.